Opthea Limited Sponsored ADR (OPT) has released an update.
Opthea Limited, a clinical-stage biopharmaceutical company, is set to present its advancements in treating retinal diseases at two major investor conferences in September 2024, with CEO Frederic Guerard leading the presentations. The company is currently evaluating its lead product candidate, sozinibercept, in Phase 3 clinical trials for its potential to enhance vision when used with standard treatments. These presentations at the H.C. Wainwright and Cantor Global Healthcare Conferences will be accessible via webcast on the company’s website.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.
